Chest, Vol 105, 1411-1419, Copyright © 1994 by American College of Chest Physicians

ARTICLES

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group

Combination bronchodilator therapy for chronic obstructive pulmonary disease (COPD) is available widely throughout the world except in North America. Previous studies have yielded conflicting results regarding the advantages of combining anticholinergic therapy with sympathomimetic therapy in COPD. We report the results of a 12-week prospective, double-blind, parallel-group evaluation of the use of the following: albuterol, a beta-adrenergic agent; ipratropium, an anticholinergic agent; or a combination of the two, administered by metered-dose inhaler to patients with moderately severe stable COPD. Following baseline studies, 534 patients were given one of the three test bronchodilator preparations to be used at home four times daily in addition to oral theophylline and corticosteroids as required. The doses of the latter two drugs were kept stable. Subjects were tested on days 1, 29, 57, and 85. Analysis of 1-s forced expiratory volume (FEV1) curves on those test days indicated that the combination was superior to either single agent alone in peak effect, in the effect during the first 4 h after dosing, and in the total area under the curve of the FEV1 response. The mean peak percent increases in FEV1 over baseline on the four test days were 31 to 33 percent for the combination, 24 to 25 percent for ipratropium, and 24 to 27 percent for albuterol. The differences between the combination and its components were statistically significant on all test days. The AUC0-4 means for the combination were 21 to 44 percent greater than the ipratropium means and 30 to 46 percent greater than the albuterol means. Similar changes were noted in the forced vital capacity curves. Symptom scores did not change over time and did not differ among the treatment groups. We conclude that the combination of ipratropium and albuterol, when given by metered-dose inhaler to patients with COPD, is more effective than either of the two agents alone. The advantage of the combination is apparent primarily during the first 4 h after administration. The availability of combination therapy by metered-dose inhaler should help to improve patient compliance.

This article has been cited by other articles:

				B. R. Celli Update on the Management of COPD Chest, June 1, 2008; 133(6): 1451 - 1462. [Abstract] [Full Text] [PDF]

				A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD Chest, June 1, 2006; 129(6): 1693 - 1708. [Abstract] [Full Text] [PDF]

				J. A. van Noord, J. L. Aumann, E. Janssens, J. Verhaert, J. J. Smeets, A. Mueller, and P. J. G. Cornelissen Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD Chest, March 1, 2006; 129(3): 509 - 517. [Abstract] [Full Text] [PDF]

				D. E. Niewoehner, K. Rice, and S. Kesten Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium Ann Intern Med, January 17, 2006; 144(2): 148 - 149. [Full Text] [PDF]

				B. R. Celli Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism. Proceedings of the ATS, January 1, 2006; 3(1): 58 - 65. [Abstract] [Full Text] [PDF]

				J. F. Donohue Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects Proceedings of the ATS, November 1, 2005; 2(4): 272 - 281. [Abstract] [Full Text] [PDF]

				W. Vincken Bronchodilator treatment of stable COPD: long-acting anticholinergics Eur. Respir. Rev., September 1, 2005; 14(94): 23 - 31. [Abstract] [Full Text] [PDF]

				P. M. A. Calverley Long-acting inhaled bronchodilators in COPD: how many drugs do we need? Eur. Respir. J., August 1, 2005; 26(2): 190 - 191. [Full Text] [PDF]

				R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]

				F. A. El-Kassimi and N. A. Hanania Differentiating Asthma and COPD Patients Chest, August 1, 2004; 126(2): 653 - 655. [Full Text] [PDF]

				E. R. Sutherland and R. M. Cherniack Management of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., June 24, 2004; 350(26): 2689 - 2697. [Full Text] [PDF]

				B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A.S. Buist, P.M.A. Calverley, N. Chavannes, T. Dillard, B. Fahy, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur. Respir. J., June 1, 2004; 23(6): 932 - 946. [Full Text] [PDF]

				R. Buhl and S. G. Farmer Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142. [Abstract] [Full Text] [PDF]

				D. P. Tashkin and C. B. Cooper The Role of Long-Acting Bronchodilators in the Management of Stable COPD Chest, January 1, 2004; 125(1): 249 - 259. [Abstract] [Full Text] [PDF]

				B. R. Celli A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease JAMA, November 26, 2003; 290(20): 2721 - 2729. [Full Text] [PDF]

				D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review JAMA, November 5, 2003; 290(17): 2301 - 2312. [Abstract] [Full Text] [PDF]

				D. E Niewoehner Review: ipratropium is not more effective than {beta}2 agonists for acute exacerbations of chronic obstructive pulmonary disease Evid. Based Med., May 1, 2003; 8(3): 74 - 74. [Full Text] [PDF]

				D. Tashkin and S. Kesten Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses Chest, May 1, 2003; 123(5): 1441 - 1449. [Abstract] [Full Text] [PDF]

				W MacNee and P M A Calverley Chronic obstructive pulmonary disease * 7: Management of COPD Thorax, March 1, 2003; 58(3): 261 - 265. [Abstract] [Full Text] [PDF]

				N. Wolkove, H. Kamel, M. Rotaple, and M. A. Baltzan Jr. Use of a Mucus Clearance Device Enhances the Bronchodilator Response in Patients With Stable COPD Chest, March 1, 2002; 121(3): 702 - 707. [Abstract] [Full Text] [PDF]

				R. L. ZuWallack, D. A. Mahler, D. Reilly, N. Church, A. Emmett, K. Rickard, and K. Knobil Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD Chest, June 1, 2001; 119(6): 1661 - 1670. [Abstract] [Full Text] [PDF]

				A. D. D'Urzo, M. C. De Salvo, A. Ramirez-Rivera, J. Almeida, L. Sichletidis, G. Rapatz, and J. Kottakis In Patients With COPD, Treatment With a Combination of Formoterol and Ipratropium Is More Effective Than a Combination of Salbutamol and Ipratropium : A 3-Week, Randomized, Double-Blind, Within-Patient, Multicenter Study Chest, May 1, 2001; 119(5): 1347 - 1356. [Abstract] [Full Text] [PDF]

				S. Benayoun, P. Ernst, and S. Suissa The Impact of Combined Inhaled Bronchodilator Therapy in the Treatment of COPD Chest, January 1, 2001; 119(1): 85 - 92. [Abstract] [Full Text] [PDF]

				D. COOK, G. GUYATT, E. WONG, R. GOLDSTEIN, M. BEDARD, P. AUSTIN, H. RAMSDALE, R. JAESCHKE, and M. SEARS Regular Versus As-Needed Short-Acting Inhaled {beta}-Agonist Therapy for Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 85 - 90. [Abstract] [Full Text]

				R. Casaburi, D. D. Briggs Jr., J. F. Donohue, C. W. Serby, S. S. Menjoge, and T. J. Witek Jr. The Spirometric Efficacy of Once-Daily Dosing With Tiotropium in Stable COPD : A 13-Week Multicenter Trial Chest, November 1, 2000; 118(5): 1294 - 1302. [Abstract] [Full Text] [PDF]

				M. R. LITTNER, J. S. ILOWITE, D. P. TASHKIN, M. FRIEDMAN, C. W. SERBY, S. S. MENJOGE, and T. J. WITEK Jr. Long-Acting Bronchodilation with Once-Daily Dosing of Tiotropium (Spiriva) in Stable Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1136 - 1142. [Abstract] [Full Text]

				D. E. NIEWOEHNER, D. COLLINS, and M. L.E. f. t. D. o.  Veterans Affairs Cooperative Study Relation of FEV1 to Clinical Outcomes during Exacerbations of Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1201 - 1205. [Abstract] [Full Text]

				M. Cazzola, F. Di Perna, S. Centanni, C. Califano, C. F. Donner, M. D'Amato, and G. D'Amato Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease Thorax, December 1, 1999; 54(12): 1083 - 1086. [Abstract] [Full Text]

				T. L. Petty, D. A. Mahler, J. F. Donohue, and K. A. Rickard Apples and Oranges : Flaws and Guffaws Chest, October 1, 1999; 116(4): 1137 - 1138. [Full Text] [PDF]

				P. M. Dorinsky, C. Reisner, G. T. Ferguson, S. S. Menjoge, C. W. Serby, and T. J. Witek Jr. The Combination of Ipratropium and Albuterol Optimizes Pulmonary Function Reversibility Testing in Patients With COPD Chest, April 1, 1999; 115(4): 966 - 971. [Abstract] [Full Text] [PDF]

				G. W. Smetana Preoperative Pulmonary Evaluation N. Engl. J. Med., March 25, 1999; 340(12): 937 - 944. [Full Text] [PDF]

				M. Friedman, C. W. Serby, S. S. Menjoge, J. D. Wilson, D. E. Hilleman, and T. J. Witek Jr. Pharmacoeconomic Evaluation of a Combination of Ipratropium Plus Albuterol Compared With Ipratropium Alone and Albuterol Alone in COPD Chest, March 1, 1999; 115(3): 635 - 641. [Abstract] [Full Text] [PDF]

				S. Campbell For COPD a Combination of Ipratropium Bromide and Albuterol Sulfate Is More Effective Than Albuterol Base Arch Intern Med, January 25, 1999; 159(2): 156 - 160. [Abstract] [Full Text] [PDF]

				J. E. REPINE, A. BAST, I. LANKHORST, and The Oxidative Stress Study Gro Oxidative Stress in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 341 - 357. [Full Text]